Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Overview
=================
Brief Summary
-----------------
Efficacy and tolerability study in severe chronic obstructive pulmonary disease (COPD) patients.

Detailed Description
-----------------
Efficacy and tolerability study of Symbicort Turbuhaler (160/4.5µg/inhalation,2inhalations twice daily) added to Atrovent (20µg/inhalation, 2 inhalations 4 times daily) + theophylline SR(0.1g/tablet, 1 tablet p.o. twice daily) compared with Atrovent + theophylline SR in severe COPD patients.

Official Title
-----------------
Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.

Conditions
-----------------
Chronic Obstructive Pulmonary Disease (COPD)

Intervention / Treatment
-----------------
* Drug: Drug: Budesonide/formoterol (Symbicort Turbuhaler
* Drug: Drug: ipratropium (AtroventTM)
* Drug: theophylline SR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed and dated informed consent Men or women patients ≥ 40 years of age Diagnosis of COPD with symptoms for more than 2 years and there is a history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before Visit 2 Forced Expiratory Volume in 1 second (FEV1) ≤50% of predicted normal value, pre-bronchodilator and Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) < 70%, pre-bronchodilator Total symptom score of 2 or more per day for at least half of run-in period (breathing, cough and sputum scores from the diary card) and complete morning recordings of Digital Peak Flow Meter data at least 7 out of the last 10 days of the run-in period Exclusion Criteria: A history of asthma and seasonal allergic rhinitis before 40 years of age Patients who have experienced exacerbation of COPD requiring hospitalisation and /or emergency room treatment and/or a course of oral steroids and/or intravenous corticosteroids and/or antibiotics within 4 weeks prior to Visit 2 and/or during run-in period Patients with relevant cardiovascular disorder judged by the investigator Patients with glaucoma, prostatic hyperplasia or bladder-neck obstruction judged by the investigator Women who are pregnant, breast-feeding or of child-bearing potential judged by the investigator

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily) | Drug: Drug: Budesonide/formoterol (Symbicort Turbuhaler<br>* budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)<br>Drug: Drug: ipratropium (AtroventTM)<br>* ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)<br>Drug: theophylline SR<br>* theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)<br>|
| Other: 2<br>ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily) | Drug: Drug: ipratropium (AtroventTM)<br>* ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)<br>Drug: theophylline SR<br>* theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pre-dose FEV1 | Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value | Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-dose FEV1 at 5 Minutes | Ratio of post-dose FEV1 at 5 minutes to baseline value | Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug | 
| Post-dose FEV1 at 60 Minutes | Ratio of post-dose FEV1 at 60 minutes to baseline value | Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12) | 
| Pre-dose FVC | Ratio of pre-dose FVC (Forced Vital Capacity) to baseline | Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12) | 
| Post-dose FVC at 5 Minutes | Ratio of post-dose FVC at 5 minutes to baseline | Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12) | 
| Post-dose FVC at 60 Minutes | Ratio of post-dose FVC at 60 minutes to baseline | Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12) | 
| Pre-dose IC | Ratio of pre-dose IC (Inspiratory Capacity) to baseline | Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12) | 
| Post-dose IC at 60 Minutes | Ratio of post-dose IC at 60 minutes to baseline | Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12) | 
| Pre-dose PEF in Last Week of Treatment | Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment | 
| Pre-dose PEF in First Week of Treatment | Change in pre-dose morning PEF from run-in period to first week of treatment | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured before inhalation of study drug in the first week of treatment | 
| Pre-dose PEF in Whole Treatment Period | Change in pre-dose morning PEF from run-in period to whole treatment period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period (12 weeks) | 
| Post-dose PEF in Last Week of Treatment | Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment | 
| Post-dose PEF in First Week of Treatment | Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured at 5 minutes after inhalation of study drug in the first week of treatment | 
| Post-dose PEF in Whole Treatment Period | Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period (12 weeks) | 
| Use of Reliever Medication During Day in the Last Week on Treatment | Change in the number of inhalations of reliever medication during day from run-in to the last week on treatment | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment | 
| Use of Reliever Medication During Day in the First Week on Treatment | Change in the number of inhalations of reliever medication during day from run-in to the first week on treatment | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment | 
| Use of Reliever Medication During Day in the Whole Treatment Period | Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period (12 weeks) | 
| Change in COPD Symptoms - Breathing | Change in breathing symptom score (from 0 (none) to 4 (severe)) from run-in period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks) | 
| COPD Symptoms - Cough | Change in cough symptom score (from 0 (none) to 4 (almost constant)) from run-in period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks) | 
| COPD Symptoms Sputum | Change in sputum symptom score (from 0 (none) to 4 (severe)) from run-in period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks) | 
| COPD Exacerbations | Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms | Whole treatment period (12 weeks) | 
| Use of Reliever Medication During Night in the Last Week on Treatment | Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the last week on treatment | 
| Use of Reliever Medication During Night in the First Week on Treatment | change in the number of inhalations of reliever medication during day from run-in to the first week on treatment | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment | 
| Use of Reliever Medication During Night in the Whole Treatment Period | Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period | Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the whole treatment period (12 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Severe chronic obstructive pulmonary disease (COPD) patients